Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 24

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 24
---
 efforts on developing innovative treatments for chronic and degenerative diseases, with key projects including AstroRx, a cell -basedtherapy for ALS, and IsletRx, a diabetes treatment aimed at insulin -dependentpatients. Both programs are in advanced clinical development stages and reflect Kadimastem’s commitment to tackling complex medical challenges. To support its research and development efforts, Kadimastem has established significant collaborations with leading academic institutions, including the Hadassah Medical Organization and Yeda Research and Development Company, granting it access to licensed stem cell patents and technical expertise. It has also secured funding from notable sources such as the Israel Innovation Authority and the BIRD Foundation, which have enabled Kadimastem to scale its operations and accelerate product development. As well as engagement with an international CDMO for large -scalebatch manufacturing. Sales and Marketing Expenses Kadimastem had no sales and marketing expenses in each of the six months ended June 30, 2025, and June 30, 2024. General and Administrative Expenses General and administrative expenses for the six months ended June 30, 2025 were $685,659, representing an increase of $309,373 compared to $376,286 for the six months ended June 30, 2024. The increase was primarily attributable to an increase in share -basedpayment expenses, office rent and maintenance, and other general expenses. This was partially offset by lower professional services, legal services and salaries. Other Expenses (Expenses for merger with NLS) Other expenses (expenses for Merger with NLS) for the six months ended June 30, 2025 were $100,889, representing the expenses in connection with the Merger with NLS. There we no such expenses for the six months ended June 30, 2024, as the term -sheetagreement with NLS was signed in July 2024. Operating Loss Operating loss for the six months ended June 30, 2025, was $1,362,423, representing an increase of $575,742 compared to $786,681 for the six months ended June 30, 2024. The increase was primarily due to an increase in research and development expenses mainly batch, manufacturing, and share -basedcompensation in general and administrative expenses. 14 Financial expenses net Finance expenses, net for the six months ended June 30, 2025, were $9,892,996, representing an increase of $9,407,885, compared to $485,